Prenetics Posts $64.1M in Third-Quarter Revenue
PRE sits 57% above its 52-week low of $11.365.
Summary
Prenetics reported third-quarter revenue of $64.1M, up 228% year over year, and posted a loss of $1.45 per share. The company is small — roughly $277M market cap — so a quarterly revenue figure of this size is meaningful relative to its size, and the IM8 consumer-health brand has been the growth engine behind recent guidance raises. IM8 reported Q3 2026 revenue growth of 266% YoY, with its earliest customers having returned more than 3x their acquisition cost in under two years. Prenetics reaffirmed FY 2026 total revenue guidance of $220–230 million and FY 2027 IM8 revenue guidance of $400 million+, while raising its H2 EBITDA loss outlook. This lands after a run of brand-building news: the 10-year Care Bears license with Authentic Brands Group on November 5 and Diplo named a Global Ambassador on November 17. Watch for the full release and any updated outlook, plus the CFO transition to Brian Rosin effective December 31, 2026.
At the time of this announcement, PRE was trading at $17.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.6M. The 52-week trading range was $11.37 to $27.24. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.